Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
You may also be interested in...
Warnings In 2019, AERs In 2009: Touchstones Toward Homeopathic Guidance
Priority enforcement areas listed in draft guidance note delivery formats other than oral and topical, such as nasal gel product that was early alarm in FDA's evaluation of safety and efficacy across homeopathic market. Recent warnings also noted in revised draft.
Zicam Maker Matrixx Settles With Shareholders Over H.I.G. Buyout
Matrixx Initiatives remains mired in multiple lawsuits despite settling litigation with shareholders over the firm’s handling of its 2010 buyout.
Matrixx Decision Raises More Disclosure Questions – Law Professor
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.